7Baggers
Quarterly
Annual
    Unit: USD2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-03-31 
      
    		                   
      revenues:
    		                   
      product revenue
    		193,954,000 123,590,000 190,013,000 135,740,000 92,933,000 43,823,000 35,114,000 17,664,000 9,698,000 1,151,000          
      collaboration and other revenue
    		21,125,000 195,262,000                  
      total revenues
    		215,079,000 318,852,000                  
      operating expenses:
    		                   
      cost of sales
    		35,741,000 26,342,000                  
      research and development
    		218,480,000 119,099,000 91,137,000 85,664,000 77,428,000 107,111,000 73,459,000 57,044,000 42,425,000 56,070,000 66,019,000 61,674,000 175,977,000 41,003,000 37,958,000 47,362,000 29,052,000 75,579,000 10,740,000 
      selling, general and administrative
    		250,455,000 227,243,000 219,458,000 164,511,000 170,057,000 159,523,000 122,387,000 119,533,000 124,802,000 95,601,000          
      total operating expenses
    		504,676,000 372,684,000 310,595,000 250,175,000 247,485,000 266,634,000 195,846,000 176,577,000 167,227,000 151,671,000 134,989,000 90,456,000 199,212,000 54,465,000 48,066,000 54,936,000 38,116,000 83,436,000 14,497,000 
      income from operations
    		-289,597,000 -53,832,000 -156,531,000 -139,949,000 -171,891,000 -235,673,000 -170,700,000 -163,157,000 -160,587,000 -150,944,000 -134,989,000 -90,456,000 -199,212,000 -54,465,000 -48,066,000 -54,936,000 -38,116,000   
      yoy
    		68.48% -77.16% -8.30% -14.22% 7.04% 56.13% 26.45% 80.37% -19.39% 177.14% 180.84% 64.66% 422.65%       
      qoq
    		437.96% -65.61% 11.85% -18.58% -27.06% 38.06% 4.62% 1.60% 6.39% 11.82% 49.23% -54.59% 265.76% 13.31% -12.51% 44.13%    
      operating margin %
    		                   
      other income:
    		                   
      interest expense
    		-17,114,000 -17,216,000 -16,937,000 -9,047,000 -7,836,000 -7,731,000 -7,801,000 -4,608,000 -172,000      -5,000 -12,000 -13,000   
      interest expense on mandatorily redeemable preferred shares
    		-8,077,000 -7,917,000 -8,164,000 -8,144,000 -8,042,000 -7,943,000              
      interest expense on liability related to sale of future royalties
    		-18,045,000 -17,314,000 -17,110,000 -15,488,000 -14,499,000 -13,508,000              
      change in fair value of derivatives
    		-111,197,000 3,604,000 760,000 -1,893,000 -1,490,000 -210,000 -12,250,000 -1,940,000            
      gain from equity method investment
    		     5,261,000              
      other income
    		2,229,000 81,000 -2,502,000 -5,000 -3,051,000 -1,700,000              
      total other income
    		-152,204,000 -38,762,000 -43,953,000 -34,577,000 -34,918,000 -25,831,000 -42,530,000 -29,482,000 -19,689,000 -21,299,000 -14,346,000 -15,388,000 -11,800,000 -7,730,000 -6,490,000 -6,344,000 -1,128,000   
      income before benefit from income taxes
    		-441,801,000 -92,594,000   -206,809,000 -261,504,000 -213,230,000 -192,639,000 -180,276,000 -172,243,000 -149,335,000 -105,844,000 -211,012,000 -62,195,000 -54,556,000 -61,280,000 -39,244,000   
      benefit from income taxes
    		84,000 24,303,000   4,350,000 3,824,000 4,886,000 3,989,000 658,000 694,000 -71,000 323,000 58,000 109,000 194,000 161,000 25,000 87,000 193,000 
      net income
    		-441,885,000 -116,897,000 -199,581,000 -172,328,000 -211,159,000 -265,328,000 -218,116,000 -196,628,000            
      yoy
    		109.27% -55.94% -8.50% -12.36%                
      qoq
    		278.01% -41.43% 15.81% -18.39% -20.42% 21.65% 10.93%             
      net income margin %
    		                   
      net income attributable to non-controlling interests
    		498,000 498,000                  
      deemed dividend upon repurchase of preferred shares in consolidated subsidiary
    		 -92,673,000                  
      net income attributable to common shareholders of biohaven pharmaceutical holding company ltd.
    		-441,387,000 -209,072,000             -54,750,000 -61,441,000 -39,269,000 -85,462,000 -22,753,000 
      net income per share
    		-6.21 -2.97 -3 -2.63 -3.23 -4.27 -3.64 -3.27 -3.08 -3.07 -2.87 -2.04 -4.67 -1.41 -1.33 -1.53 -1.01 -2.32 -1.74 
      weighted-average common shares outstanding—basic and diluted
    		71,043,693 70,332,274 64,677,823 65,389,574 65,112,179 62,040,715 58,732,415 59,677,989 58,742,329 56,412,439 48,489,890 52,077,240 45,226,434 44,242,070 39,188,458 40,147,735 38,942,545 36,793,090 13,088,861 
      comprehensive loss:
    		                   
      other comprehensive loss, net of tax
    		-3,413    -129               
      comprehensive loss
    		-445,298 -119,222 -162,261.75 -172,526 -211,288 -265,233              
      less: comprehensive loss attributable to non-controlling interests
    		498 498 -353 -512 -540 -360              
      comprehensive loss attributable to biohaven pharmaceutical holding company ltd.
    		-444,800 -118,724 -161,908.75 -172,014 -210,748 -264,873              
      other comprehensive income, net of tax
    		 -2,325 -58 -198  95              
      cost of goods sold
    		  35,949,000 25,514,000 17,339,000 12,862,000 9,968,000 4,244,000 3,058,000 424,000          
      gross profit
    		  154,064,000 110,226,000 75,594,000 30,961,000 25,146,000 13,420,000 6,640,000 727,000          
      yoy
    		  512.68% 721.36% 1038.46% 4158.73%              
      qoq
    		  39.77% 45.81% 144.16% 23.12% 87.38% 102.11% 813.34%           
      gross margin %
    		                   
      income before benefit for income taxes
    		  -160,709,750 -174,526,000                
      benefit for income taxes
    		  1,494,000 -2,198,000                
      less: net income attributable to non-controlling interests
    		  -398,000 -512,000 -540,000 -360,000 -380,000 -1,439,000            
      net income attributable to biohaven pharmaceutical holding company ltd.
    		  -199,183,000 -171,816,000 -210,619,000 -264,968,000 -217,736,000 -195,189,000            
      non-cash interest expense on mandatorily redeemable preferred shares
    		      -7,759,000 -7,310,000 -6,993,000 -5,561,000 -4,378,000 -4,378,000 -3,955,000       
      non-cash interest expense on liability related to sale of future royalties
    		      -13,288,000 -11,955,000 -11,570,000 -8,425,000 -7,308,000 -7,308,000 -5,151,000 -6,813,000 -5,592,000 -5,633,000 -501,000   
      income from equity method investment
    		      -690,000 -607,000 -1,485,000 -1,380,000 -1,768,000 -1,993,000 -1,415,000 -900,000 -742,000 -697,000 -641,000   
      other
    		      -819,500 -3,062,000 -119,000 -152,000 3,000 8,000 -16,000 -17,000 -151,000 -2,000 27,000   
      change in fair value of derivative liability
    		        650,000 -5,781,000 -895,000 -1,717,000 -1,263,000      289,000 
      net income and comprehensive loss
    		        -180,934,000 -172,937,000 -149,264,000 -106,167,000 -211,070,000 -62,304,000 -54,750,000 -61,441,000 -39,269,000   
      general and administrative
    		          68,970,000 28,782,000 23,235,000 13,462,000 10,108,000 7,574,000 9,064,000 7,857,000 3,757,000 
      change in fair value of warrant liability
    		                   
      change in fair value of contingent equity liability
    		                   
      accretion of beneficial conversion feature on series a preferred shares
    		                   
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.